Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) announced publication in Obesity of Phase 2 VENTURE results for weekly subcutaneous VK2735, a dual GLP-1/GIP receptor agonist. The 13-week trial met its primary and secondary endpoints, showing mean body-weight reductions up to 14.7% from baseline with no plateau and a safety profile in which most adverse events were reported as mild or moderate. Viking is advancing VK2735 in the registrational VANQUISH Phase 3 program (78-week dosing); VANQUISH-1 has ~4,650 participants enrolled and VANQUISH-2 is enrolling ~1,100. An exploratory maintenance study (≈180 subjects) also completed enrollment.
Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment in a Phase 1 maintenance dosing study of VK2735, a dual GLP-1/GIP agonist being developed in oral and subcutaneous formulations for obesity. The randomized, double-blind, placebo-controlled study enrolled ~180 adults (BMI ≥30) who received 19 weeks of weekly VK2735 or placebo, then were randomized to maintenance regimens including monthly, every-other-week, weekly subcutaneous, daily or weekly oral dosing, or placebo through Week 31. Objectives include safety, tolerability, and pharmacokinetics; exploratory endpoints assess body-weight change from baseline and from Week 19. Viking also notes ongoing Phase 3 VANQUISH-1 (≈4,650 enrolled) and VANQUISH-2 (≈1,100 planned) studies of weekly subcutaneous VK2735 for up to 78 weeks, with results expected later in 2026.
Viking Therapeutics (NASDAQ: VKTX) announced on January 7, 2026 the appointment of Neil Aubuchon as chief commercial officer. Aubuchon brings more than two decades of global commercialization and marketing experience across Amgen, Eli Lilly and most recently as CCO at AbCellera.
The company said Aubuchon will lead commercialization strategy for VK2735, described as a potentially best-in-class GLP-1/GIP dual agonist currently in Phase 3 trials for obesity, and will support partner engagement and market preparation.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12-15, 2026. The presentation is scheduled for 2:15–2:55 p.m. PT on Monday, January 12, 2026. Dr. Lian will also participate in one-on-one meetings. A live webcast will be accessible from Viking Therapeutics' Investors & Media Webcasts page, and a replay will be posted after the conference.
Viking Therapeutics (NASDAQ: VKTX) announced on November 19, 2025 that enrollment is complete in the Phase 3 VANQUISH-1 trial of subcutaneous VK2735 ahead of schedule and above target. The randomized, double-blind, placebo-controlled trial enrolled ~4,650 adults with obesity or overweight plus comorbidity, randomized to VK2735 7.5 mg, 12.5 mg, 17.5 mg, or placebo. The study will evaluate percent change in body weight at 78 weeks as the primary endpoint and includes secondary/exploratory responder endpoints (≥5%, ≥10%, ≥15%, ≥20% weight loss) plus a 52-week extension. Viking said VANQUISH-2 (type 2 diabetes with obesity) is enrolling and expects enrollment completion in Q1 2026. Prior Phase 2 VENTURE showed up to 14.7% mean weight reduction after 13 weekly doses with generally mild-to-moderate adverse events.
Viking Therapeutics (NASDAQ: VKTX) presented exploratory Phase 2 VENTURE data for subcutaneous VK2735 at ObesityWeek 2025 showing improvements in cardiometabolic status after 13 weeks.
Key findings: 78% of VK2735-treated prediabetic patients shifted to normoglycemic vs 29% placebo (p=0.0008); 68% of patients with metabolic syndrome no longer met criteria vs 38% placebo (p=0.02). Up to 14.7% mean body-weight reduction and up to 88% achieved ≥10% weight loss; most drug-related TEAEs (92%) were mild or moderate. Viking also highlighted the Phase 3 VANQUISH-1 trial design.
Viking Therapeutics (NASDAQ: VKTX) will participate in two investor conferences in November 2025.
Stifel 2025 Healthcare Conference: management will hold a fireside chat and investor meetings on Nov 11, 2025 (4:40–5:10 p.m. ET) in New York.
Jefferies 2025 Global Healthcare Conference – London: management will deliver a corporate presentation and meet investors on Nov 19, 2025 (8:00–8:25 a.m. GMT / webcast available) in London; a live webcast and replay will be available on Viking's Investors & Media Webcasts page.
Viking Therapeutics (NASDAQ: VKTX) will present clinical data and study designs for its obesity program VK2735 at ObesityWeek® 2025 (Nov 4–7, 2025) and at AHA Scientific Sessions 2025 (Nov 7–10, 2025).
ObesityWeek highlights: an exploratory analysis from the Phase 2 VENTURE study reporting 13-week effects of weekly subcutaneous VK2735 on weight, prediabetes prevalence, and metabolic syndrome, plus the Phase 3 VANQUISH-1 study design for subcutaneous VK2735 in adults with overweight or obesity.
AHA highlights: the Phase 3 VANQUISH-2 study design in Type 2 diabetes with obesity and an analysis of cardiometabolic condition prevalence across BMI categories. Presentation dates/times and presenting authors are listed for each poster.
Viking Therapeutics (NASDAQ:VKTX) reported Q3 2025 results and a corporate update on Oct 22, 2025. Key highlights include a $715 million quarter-end cash balance, Phase 3 VANQUISH program for subcutaneous VK2735 proceeding on schedule, and Phase 2 oral VENTURE topline showing up to 12.2% mean weight loss after 13 weeks. Prior subcutaneous data showed up to 14.7% mean weight loss. The company initiated a maintenance dosing study and plans an IND for an amylin agonist program in 1Q26. Q3 R&D expense rose to $90.0M from $22.8M year-ago.
Viking Therapeutics (NASDAQ: VKTX) initiated a Phase 1 randomized, double-blind, placebo-controlled maintenance dosing study of VK2735 in approximately 180 adults with obesity on Oct 21, 2025. All participants receive initial weekly subcutaneous VK2735 or placebo for 19 weeks, then transition to maintenance arms: monthly subcutaneous, weekly oral, daily oral, or placebo through Week 31.
The study will evaluate safety, tolerability, and pharmacokinetics, with exploratory endpoints including change in body weight from baseline and from Week 19 to Week 31. Viking expects to report results in 2026. Viking is also conducting two Phase 3 weekly subcutaneous trials: VANQUISH-1 (~4,500) and VANQUISH-2 (~1,100), each dosed for 78 weeks.